Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Terra Wonsettler, PharmD, MBA
Advertisement
Articles by Terra Wonsettler, PharmD, MBA
Advertisement
Latest Updated Articles
Cancer Drugs Speed to Accelerated Approvals, Then Hit the Brakes in Timely, Clinically Beneficial Confirmatory TrialsPublished: August 15th 2024 | Updated:
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?Published: June 12th 2024 | Updated:
The Dangerous Intersection of Breast Cancer and Cardiovascular Disease: A Call for Improved PreventionPublished: December 19th 2024 | Updated:
Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”Published: February 7th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
4
Mediterranean Diet Improves Psoriasis Severity, Study Finds
5
